Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 14, 2021 17:08 ET | Source: Landos Biopharma, Inc.

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and...
June 14, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced Artificial Intelligence (A.I.)...
May 25, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference

BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop...
May 19, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors

BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for...
May 17, 2021 07:15 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates

Completed initial public offering of common stock, raising approximately $100 million in gross proceeds Following positive Phase 2 results of omilancor in ulcerative colitis, including...
May 17, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma与联拓生物宣布独家合作和许可协议，将携手在中国和亚洲特定市场对新药Omilancor和NX-13进行开发和商业化

布莱克斯堡（美国弗吉尼亚州）、上海（中国）和普林斯顿（美国新泽西州）, May 17, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma,...
May 17, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets

BLACKSBURG, Va., and SHANGHAI, China and PRINCETON, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery...
May 06, 2021 16:01 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease

Company’s second omilancor program entering a Phase 2 study with plans to pursue at least five autoimmune indications Topline results are expected in the second quarter of 2022 BLACKSBURG, Va., May ...
April 29, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis

Landos’ second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients Topline results are expected in the first quarter of 2022 ...
April 26, 2021 07:00 ET | Source: Landos Biopharma, Inc.

Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting

Robust preclinical data supports breadth and growth of Landos’ autoimmune-focused pipelineCompany expects to submit an IND for omilancor as a topical treatment for psoriasis in 2H 2021Company expects...